Recent Updates
Recently added Catalysts

Commercial acetaminophen

Phase 3

Post-operative Dental Pain | Small molecule | Pain |Johnson & Johnson|Last Updated: Apr 15, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment664

FDA Designations

No designations recorded

Clinical trial landscape

Commercial acetaminophen · 1 trial · 1 indication

Phase 3 1
NCT03224403Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental PainPost-operative Dental Pain
COMPLETED664 Analytics
PHASE3COMPLETED
Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental Pain
Post-operative Dental PainUnlock trial analytics

Study Endpoints

Primary Endpoints

Time to Confirmed Perceptible Pain Relief
within 4 hours

Minutes until confirmed perceptible pain relief is achieved. Stopwatch is started after the participant takes the study medication. The participant is instructed to stop the stopwatch when they first begin to feel any pain relief. The perceptible pain relief is confirmed if the participant also stopped the second stopwatch indicating meaningful pain relief.

Secondary Endpoints

Time to Meaningful Pain Relief
Within 4 hours
Percentage of Participants With Confirmed Perceptible Relief From 30 Minutes to Successively Earlier Minutes in One-minute Increments - 30 Minutes
by 30 minutes
Percentage of Participants With Confirmed Perceptible Relief From 30 Minutes to Successively Earlier Minutes in One-minute Increments - 29 Minutes
by 29 minutes
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Test acetaminophenEXPERIMENTALTest acetaminophen 1000 mg dose
Commercial acetaminophenACTIVE_COMPARATORCommercial acetaminophen 1000 mg dose
Commercial ibuprofenACTIVE_COMPARATORCommercial ibuprofen, 400 mg dose
PlaceboPLACEBO_COMPARATORPlacebo

Interventions

NameTypeDescription
Test acetaminophenDRUGsingle dose of 2 Test acetaminophen 500 mg tablets
Commercial acetaminophenDRUGsingle dose of 2 acetaminophen 500 mg caplets
Commercial ibuprofenDRUGSingle dose of 2 ibuprofen 200 mg Liquid-filled Capsules
PlaceboDRUG2 placebo caplets
Unlock Study Design Details

Eligibility Criteria

Age Range17 Years to 50 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. 17 to 50 years old 2. Weigh 100 lbs. or greater and have a body mass index (BMI) of 18 to 30 (inclusive) 3. Dental extraction of three or four third molars 4. Meets post-surgical pain criteria 5. Females of childbearing age must be willing to use acceptable method of birth co...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Commercial acetaminophen

What is Commercial acetaminophen used for?

Commercial acetaminophen is used for the treatment of post-operative dental pain. It is a small molecule being developed by Johnson & Johnson for this indication. The drug has completed a Phase 3 clinical trial in this setting.

Who makes Commercial acetaminophen?

Commercial acetaminophen is developed by Johnson & Johnson, a company traded under the ticker JNJ. The drug is being studied for post-operative dental pain and has completed a Phase 3 clinical trial.

What phase is Commercial acetaminophen in?

Commercial acetaminophen is in Phase 3 clinical development. It is an investigational drug for post-operative dental pain, and its Phase 3 trial has been completed. The drug is not yet approved and remains under clinical investigation.

What clinical trials is Commercial acetaminophen in?

Commercial acetaminophen has one completed Phase 3 trial, NCT03224403. This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of a single dose of the drug in 664 patients with post-operative dental pain in the United States.

Is Commercial acetaminophen FDA approved?

Commercial acetaminophen is not FDA approved. It is an investigational drug in Phase 3 clinical development for post-operative dental pain. Its Phase 3 trial has been completed, but approval status has not been established.